Pancreatic Adenocarcinoma Gene Copy Number and Survival Data from CPTAC and TCGA

A study investigating the amplification of genes ARHGAP29 and SLC44A3 adjacent to F3 in pancreatic adenocarcinoma (PAAD). Precision-guided copy number variation analyses were performed using data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC)-PAAD and The Cancer Genome Atlas (TCGA)-PAAD. The dataset includes Kaplan–Meier survival analyses and Pearson’s correlation tests linking gene copy numbers to overall survival, disease-free survival, and genomic instability.

Use Cases

• Correlating gene copy number variation with patient survival outcomes based on Kaplan–Meier analyses.
• Investigating the relationship between genomic instability (MSIsensor scores) and amplification of specific genes.
• Comparing gene amplification patterns and clinical outcomes across two major pancreatic cancer cohorts (CPTAC and TCGA).
• Analyzing the potential link between pro-proliferative gene amplification and venous thromboembolism risk in pancreatic cancer.

Strengths

• Analysis is based on two established cancer genomics data sources: CPTAC-PAAD and TCGA-PAAD.
• Includes statistical tests (Pearson’s correlation, Kaplan–Meier) linking specific gene amplifications to clinical outcomes.
• Dataset is licensed under CC-BY-4.0, permitting open sharing and reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is stored in an XLSM (Excel Macro-Enabled) format, which may require specific software for full functionality.

Provenance

Source

Clinical Proteomic Tumor Analysis Consortium (CPTAC)-PAAD and The Cancer Genome Atlas (TCGA)-PAAD.

Collection Method

Precision-guided copy number variation (CNV) analyses performed on the source datasets.

Freshness

Last updated 2026-05-21 10:56:38; freshness should be verified.